Vaccinia virus mature virion surface proteins (VACV MV surface proteins)

Vaccinia virus (VACV) mature virion (MV) surface proteins are a complex set of proteins embedded in the lipid envelope of the virus's most abundant infectious form. These proteins, including L1, A27, D8, and H3, are essential for the initial stages of infection, specifically mediating attachment to host cell surface glycosaminoglycans and the subsequent fusion of the viral envelope with host membranes (PMID: 15956339, 10666351). The MV surface proteins are the primary targets for neutralizing antibodies, making them the focus of both active immunization (vaccines like ACAM2000 and JYNNEOS) and passive immunization (Vaccinia Immune Globulin) (PMID: 16188997). A subset of these proteins forms the Entry Fusion Complex (EFC), which is highly conserved across the Orthopoxvirus genus and is required for delivering the viral core into the host cytoplasm (PMID: 22438551). Because the MV is the form of the virus responsible for person-to-person transmission and environmental stability, these surface proteins are critical targets for therapeutic intervention and diagnostic monitoring. Research into these proteins is vital for developing broad-spectrum countermeasures against emerging poxvirus threats such as Mpox and the potential re-emergence of smallpox.

Other names

VACV MV envelope proteinsVaccinia virus mature particle membrane proteinsOrthopoxvirus MV surface antigensL1RA27LD8LH3LA17L

Neutralization of viral infectivity by blocking host cell attachment and membrane fusion; induction of protective humoral immunity.